Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LY2 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.064 | uM | 7477.084 | 1.1612 | 1.3417 | 0.9476 | |
| LY2 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.32 | uM | 7477.084 | 1.0972 | 1.2056 | 0.9476 | |
| LY2 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1.6 | uM | 7477.084 | 1.1079 | 1.2284 | 0.9476 | |
| LY2 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 7477.084 | 2.1565 | 3.5001 | 0.9476 | |
| LY2 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 40 | uM | 7477.084 | 3.0073 | 5.3920 | 0.9476 | |
| LY2 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 200 | uM | 7477.084 | 2.3377 | 3.9001 | 0.9476 | |
| LY2 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 7477.084 | 2.3777 | 3.9886 | 0.9476 | |
| MB 157 | Unknown | Unknown | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00256 | uM | 7482.084 | 1.3618 | 1.3592 | 1.8697 | |
| MB 157 | Unknown | Unknown | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0128 | uM | 7482.084 | 1.1564 | 1.1616 | 1.8697 | |
| MB 157 | Unknown | Unknown | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.064 | uM | 7482.084 | 1.3364 | 1.3355 | 1.8697 | |
| MB 157 | Unknown | Unknown | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.32 | uM | 7482.084 | 1.2953 | 1.2969 | 1.8697 | |
| MB 157 | Unknown | Unknown | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1.6 | uM | 7482.084 | 1.4821 | 1.4685 | 1.8697 | |
| MB 157 | Unknown | Unknown | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 7482.084 | 1.2086 | 1.2133 | 1.8697 | |
| MB 157 | Unknown | Unknown | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 40 | uM | 7482.084 | 1.3131 | 1.3136 | 1.8697 | |
| MB 157 | Unknown | Unknown | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 200 | uM | 7482.084 | 1.0099 | 1.0106 | 1.8697 | |
| MB 157 | Unknown | Unknown | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 7482.084 | 1.0451 | 1.0478 | 1.8697 | |
| MCF 10A | NM | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00256 | uM | 7483.084 | 0.9241 | 0.9525 | 3.2830 | |
| MCF 10A | NM | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0128 | uM | 7483.084 | 1.0226 | 1.0137 | 3.2830 | |
| MCF 10A | NM | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.064 | uM | 7483.084 | 1.0154 | 1.0093 | 3.2830 | |
| MCF 10A | NM | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.32 | uM | 7483.084 | 1.0039 | 1.0024 | 3.2830 | |
| MCF 10A | NM | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1.6 | uM | 7483.084 | 0.9966 | 0.9979 | 3.2830 | |
| MCF 10A | NM | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 7483.084 | 0.8332 | 0.8918 | 3.2830 | |
| MCF 10A | NM | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 40 | uM | 7483.084 | 0.8445 | 0.8996 | 3.2830 | |
| MCF 10A | NM | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 200 | uM | 7483.084 | 0.4458 | 0.5637 | 3.2830 | |
| MCF 10A | NM | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 7483.084 | 0.4586 | 0.5773 | 3.2830 |